Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib plus Temozolomide in Advanced Solid Tumors and SCLC
NCT04434482Phase 2Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of senaparib in solid tumor, small cell lung cancer (SCLC), sponsored by IMPACT Therapeutics. Started Aug 2020; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04434482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04434482.